Stocks
Guggenheim Analyst Raises Merck & Co Target Price to $170
Guggenheim analyst Vamil Divan has maintained his 'buy' rating on Merck & Co (MRK.US) and increased his target price to $170. This decision is based on the analyst's past performance, which includes a success rate of 62.2% and an average return of 16.2% over the past year.
The new target price represents a significant increase from the previous target of $146. It remains to be seen how this revised forecast will impact Merck & Co's stock price in the coming months.